A Cure for a Growing Epidemic?

This impacts 4 in 10 Americans... SPECIAL OPPORTUNITIES [The Oxford Club Special Opportunities]( Note From Editorial Director Justin Fritz-Rushing: Today's edition was adapted from the May 2024 issue of our Oxford Communiqué newsletter. It highlights an epidemic that in impacts 4 in 10 Americans... and the treatments that are leading to incredible gains for some investors. --------------------------------------------------------------- A Cure for a Growing Epidemic? Matt Benjamin, Senior Markets Expert, The Oxford Club [Anthony Summers] You know something is a big deal when Oprah Winfrey goes prime time on it... Just last month, the billionaire talk show host devoted an hour-long ABC News special to the rise of a new class of weight-loss drugs and their astounding ability to treat obesity. That one word - treat - is telling here. That's because a major theme of the special was how perceptions of obesity are radically changing. Obesity is no longer considered a result of overeating, not exercising or not practicing willpower. Instead, it's viewed as a disease - like cancer - and one that can now be effectively treated. Oprah was once a proponent of portion control and exercise to treat obesity. (She was an ambassador for WeightWatchers for almost a decade but left just before this prime-time special.) But like many people, Oprah now believes that obesity, in her words, "is a disease, and it's in the brain." Obesity is more than just a disease, however. It's an epidemic, and a global one. About 4 in 10 Americans are obese (almost 8% severely so), and 1 in 8 people on the planet are obese, according to the World Health Organization. (Obesity is defined as having a body mass index of 30 or higher.) In the United States, obesity is second only to smoking as the leading cause of preventable death. It is linked to multiple health risks, including Type 2 diabetes, coronary artery disease, nonalcoholic fatty liver disease, some forms of cancer and sleep apnea, among others. And those conditions don't even touch on the trauma or emotional pain that can result from being obese. Until recently, the main treatment for obesity was lifestyle changes, primarily diet and exercise. But the data indicates those haven't worked well. Obesity prevalence in the U.S. increased from 30.5% in 2000 to 42% in 2020, according to the Centers for Disease Control and Prevention. Severe obesity increased from 4.7% to 9.2% over those two decades. According to the National Institutes of Health, the obesity epidemic began in the U.S. in the late 1970s and spread rapidly to other Western nations. And now, as developing nations become wealthier, they too are catching the obesity disease. Worldwide adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled. [Obesity Goes Global] A New Way to Treat Obesity In recent years, highly innovative treatments have emerged that are safe and effective. It started almost 40 years ago... when researchers found that a hormone called glucagon-like peptide-1, or GLP-1, is released in the gut after food intake. This "incretin hormone" boosts insulin levels and reduces appetite. In its natural form, it lasts only a few minutes in the blood. Pharmaceutical innovators then developed injectable products for diabetes that mimic the effects of GLP-1 and last longer. And they work extremely well - both to treat diabetes and to spur weight loss. They work so well that they are expected to create headwinds for food and beverage makers in the coming years, as the drugs alter appetites and reduce calorie intake. The market for anti-obesity drugs is soaring. It hit $6 billion in 2023. And Goldman Sachs estimates it will grow to 16 times that by 2030, to about $100 billion, with 1 in 8 Americans - about 15 million people - taking an anti-obesity medication. That's exactly why we hold a particular stock in our Oxford Trading Portfolio - one that's up 156% since Chief Investment Strategist Alexander Green originally recommended it in October 2022. The upside for obesity treatments is difficult to overestimate at this point. And this is a medical breakthrough every smart investor should have a stake in. If you're already a subscriber to The Oxford Communiqué, we just covered the company in the Portfolio Review section of the May 2024 issue. For those of you who are interested in joining Alex's flagship newsletter, [go here for details on the publication]( and what it has to offer. Good investing, Matt OPPORTUNITIES OF INTEREST - [Can you guess these FIVE simple letters? _ _ _ _ _ They've been the key to beating the market by more than 550% -- > Answer revealed HERE]( - [Expert Predicts Gold, Oil, Copper About to Soar Higher... Discover Why We're in a New Commodities Supercycle Right Here.]( - [For Free? Click Here to Get the Names and Ticker Symbols of the Top Dividend Stocks in the Market!]( SPONSORED [Inside Look at Pro Trader's Million-Dollar Challenge:]( [Million-Dollar Challenge]( Millionaire trader Nate Bear is on a mission to turn ANOTHER $37K into $1 million on camera inside his Daily Profits Live chat room. The week of April 22-26, get a FREE, real-time demo of how he plans to accomplish this rare milestone... AGAIN! See how you can grow your money too... just by looking over his shoulder. [Join Nate for the FREE upcoming Daily Profits Live "Open House" >>]( [The Oxford Club] You are receiving this email because you subscribed to Oxford Club Special Opportunities. Oxford Club Special Opportunities is published by The Oxford Club. Questions? Check out our [FAQs](. Trying to reach us? [Contact us here.]( Please do not reply to this email as it goes to an unmonitored inbox. [Privacy Policy]( | [Whitelist Oxford Club Special Opportunities]( | [Unsubscribe]( © 2024 The Oxford Club, LLC All Rights Reserved The Oxford Club | [105 West Monument Street](#) | [Baltimore, MD 21201](#) North America: [1.800.589.3430](#) | International: [+1.443.353.4334](#) | Fax: [1.410.329.1923](#) [Oxfordclub.com]( Your Legal Questions... Answered What is The Oxford Club? The Oxford Club is a financial publisher with a highly rated track record. We deliver unique and well-researched financial and investment ideas to our Members. What do you do? We share our team of experts' industry knowledge and timely insights with our Members so they have the financial literacy and tools needed to build a rich, fulfilling life. We do not provide any personalized financial advice or advocate the purchase or sale of any security or investment for any specific individual. Instead, the information we share is directed toward a larger audience of all subscribed Members. So you'll make me rich? Maybe! But not exactly. Our goal is to provide the research and information required to help you make you rich. Investment markets have inherent risks, and we can't guarantee future profits. Why should I trust you? We offer information based on what we think will provide the most value to our Members. Our business depends on Members' interest in our ideas and satisfaction with their results. We've been around for 30-plus years because our Members have continually chosen to stay with us (many of them for life). Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Should I still consult my investment advisor? Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.